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ABSTRACT: External beam radiotherapy (EBRT) is not a first line treat-
ment in differentiated thyroid carcinoma (DTC), but is recommended as
an adjuvant treatment in certain cases. The evidence for EBRT in DTC is
limited. A comprehensive literature search was performed. Data on
patient demographics, disease stage, treatment characteristics, and out-
comes were collected from included articles after quality appraisal. Six-
teen articles met the inclusion criteria, with a pooled population of 5114.
Only 1 study was prospective and there were no randomized controlled
trials. Most of the evidence suggests that EBRT improves locoregional
control in patients at high risk of locoregional recurrence. This was cor-
roborated by analysis of pooled patient data. Available evidence suggests
an improvement in locoregional control when EBRT is used in patients
over the age of 45 at high risk for locoregional recurrence. However,
there is a need for long-term prospective multicenter research on the
subject.VC 2015 Wiley Periodicals, Inc. Head Neck 00: 000–000, 2015
KEY WORDS: radiotherapy, thyroid carcinoma, papillary thyroid car-
cinoma, follicular thyroid carcinoma, review
INTRODUCTION
Differentiated papillary and follicular thyroid carcinomata
comprise at least 75% of thyroid cancers in the United King-
dom.1 The treatment of differentiated thyroid carcinoma
(DTC) depends on the stage and risk profile of the detected
tumor, and includes hemithyroidectomy or total thyroidec-
tomy with or without neck dissection and radioiodine treat-
ment, followed by long-term thyroid-stimulating hormone
suppression with thyroxine in medium and high risk
patients.2,3 Recurrence occurs in 10% to 15% of patients
with DTC and is most frequently confined to the neck.4
The American Thyroid Association guidelines on DTC
state that external beam radiotherapy (EBRT) “to treat the
primary tumor should be considered in patients over age
45 with grossly visible extrathyroidal extension at the
time of surgery and a high likelihood of microscopic
residual disease, and for those patients with gross residual
tumor in whom further surgery or RAI would likely be
ineffective.”5 The British Thyroid Association guidelines
recommend the use of EBRT in patients with gross evi-
dence of local tumor invasion at the time of surgery with
significant macroscopic residual disease, or in the case of
residual or recurrent tumor failing to concentrate
radioiodine.6
There are several factors contributing to the difficulty in
studying the usefulness of EBRT in DTC. The indolent
nature and low mortality rate of DTC mean large numbers
and long follow-up are needed to produce statistically sig-
nificant results. With ever-evolving cancer treatments, this
means that patients enrolled in previous trials may have
received different treatment to those enrolled more
recently. Furthermore, EBRT is reserved for a relatively
small subgroup of patients with significantly worse prog-
noses than the average patient with DTC.
Findings of published studies on the use of EBRT in
DTC are not unanimous. Some authors found no statisti-
cally significant improvements in survival but recorded
adverse effects of EBRT, thus refraining from recom-
mending its use7–9; whereas others have shown impres-
sive improvements in survival outcomes and locoregional
control in the absence of major complications and recom-
mend it in specific circumstances.10–17 These studies were
heterogeneous in their populations, methodologies, inclu-
sion criteria, and outcome measures, making collation of
evidence and application to clinical practice difficult.
There are no published systematic reviews or meta-
analyses on the use of EBRT in DTC, and a search of the
international Prospective Register of Systematic Reviews
and the Database of Abstracts of Reviews and Effects
yielded no results. This, together with the conflicting
findings on EBRT in DTC, prompted this summary of
existing evidence to better inform clinicians.
MATERIALS AND METHODS
Search strategy
Comprehensive searches were carried out independently
by 2 reviewers (J.M.F. and R.C.) using Medline,
CINAHL, EMBASE, and the Cochrane library databases.
*Corresponding author: J. M. Fussey, Institute of Head and Neck Studies and
Education, School of Cancer Sciences, University of Birmingham, Edgbaston,
Birmingham, B15 2TT, United Kingdom. E-mail: jfussey@doctors.org.uk
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Search terms and Boolean operators used were
“differentiated thyroid carcinoma” OR “thyroid neoplasms”
OR “papillary carcinoma” OR “follicular carcinoma” AND
“external beam radiotherapy” OR “radiotherapy” OR
“intensity modulated radiotherapy.” No date or language
restrictions were applied. The final search was performed
on October 15, 2014. Titles and abstracts were screened for
relevance and relevant articles were obtained for assess-
ment. Reference lists were manually searched for further
relevant articles.
Eligibility criteria
All studies relating to EBRT use in DTC were consid-
ered. Only studies that included information on patient
and tumor characteristics, treatment, and outcomes were
included. Outcomes could be survival or locoregional
control. Studies were excluded if they consisted of <10
subjects, or included patients with lymphoma, anaplastic
carcinoma, or medullary carcinoma. Finally, studies that
described the use of EBRT with palliative intent were
excluded. This was defined by the use of EBRT alone
and not as an adjunct to treatment with curative intent, or
the use of EBRT to alleviate symptoms of advanced dis-
ease. Review articles were also excluded.
Data extraction
Data from included studies were collated using a pro-
forma in Microsoft Excel (Redmond, WA). Article
authors were contacted directly to obtain further informa-
tion in cases of incomplete reported data.
Quality and risk of bias appraisal
All studies were assessed for quality and risk of bias by
both reviewers, according to a modification of the system
described in the Cochrane Handbook for Systematic
Reviews of Interventions version 5.1.0.18 Because of the
large number of retrospective, nonrandomized, nonblinded
studies on the subject, more weight was placed on
descriptions of interventions and reporting of outcomes
than randomization and blinding.
Data analysis
Data extracted from the studies included in the quanti-
tative review were analyzed using SPSS version 22 (IBM,
Armonk, NY). Patient characteristics are presented as
mean6 SE. Patient characteristics and differences in
parameters between the treatment groups in the respective
studies were examined using t tests for paired samples.
Correlation was tested using the Pearson product-moment
correlation coefficient. In all cases, a p value of .05 was
considered statistically significant.
RESULTS
Search results and study selection
This search strategy yielded a total of 821 articles. By
screening the titles alone, 765 articles could be excluded,
as they were either review articles, obviously not relating
to the use of EBRT in DTC, or obviously not eligible for
inclusion (for example, studies looking at EBRT for palli-
ation of metastases). This left 56 abstracts, of which 6
were deemed by both reviewers to be ineligible for inclu-
sion or irrelevant. Fifty full articles were then obtained
for detailed assessment. Of these, 34 were excluded for a
variety of reasons, including failure to meet eligibility cri-
teria, high risk of bias, poor study design, or insufficient
outcome data. This left 16 articles appropriate for inclu-
sion in the review and 8 of these appropriate for quantita-
tive analysis based on their comprehensive reporting of
locoregional recurrence outcomes. All decisions to
exclude studies were taken jointly by both reviewers. Fig-
ure 1 shows the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses flowchart.
Characteristics of included studies
The 16 studies selected for inclusion were published
between 1993 and 2013 and originated from 9 different
countries. Only 1 study was designed as a randomized
controlled trial, and this was subsequently downgraded to
a prospective cohort study because of low numbers of
patients consenting to randomization.8 This was the only
multicenter trial. The other studies were comprised of 9
retrospective cohort studies and 6 retrospective reviews.
A total of 5114 subjects made up the study population
from the 16 included studies. The average number of par-
ticipants per study was 320 (range, 23–1297). Characteris-
tics of the study population are detailed in Table 1. The
overall male to female ratio was 1:3.1, and 89% of the
tumors were papillary carcinomas.
Interventions
Interventions included surgery, EBRT, and radioiodine
therapy in various combinations. This led to 6 possible
treatment groups, as illustrated in Table 2. A total of
1442 patients were treated with EBRT with or without
other treatment modalities. Intensity-modulated radiother-
apy (IMRT) was used in 2 studies,19,20 with the rest using
standard EBRT. The anatomic area irradiated was
described in 14 of the 16 studies; in the majority, this
was the whole neck and upper mediastinum, with only 3
studies describing limited radiation fields focusing on the
thyroid bed.14,19 Durations of treatment ranging from 3 to
6 weeks were described, and the dose of radiation ranged
from 38 to 72 Grays in 15 to 40 fractions.
Outcomes
Length of follow-up was variable among the studies,
with a mean ranging from 2.5 to 9.9 years and median
ranging from 3.2 to 11.3 years. These wide ranges were
skewed by 4 low outliers with a mean of 2.5 years, and
medians of 3.2, 3.5, and 4.6 years.7,13,14,20 Together, these
studies with <5-year average follow-up contained 596
subjects. A summary of the main findings of each study
is illustrated in Table 3.
Locoregional control
Outcome reporting was variable between studies, of the
13 reporting overall locoregional recurrence rates; the
mean rate of recurrence was 13.2% (range, 0% to 30.4%) of
those treated with EBRT and 20.1% (range, 2.5% to
58.1%) of those not treated with EBRT. Several stud-
ies8,10–14,16,17 showed statistically significant improvements
FUSSEY ET AL.
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in locoregional control, particularly in higher risk sub-
groups. Chow et al11 reported a large retrospective cohort
study and found a statistically significant improvement in
locoregional control in the subgroup of patients with mac-
roscopic residual disease treated with EBRT compared with
those not irradiated (10-year locoregional control rate
56.2% with EBRT vs 24% with no EBRT; relative
risk5 0.36; p< .001). This study revealed a statistically
significant reduction in the rate of distant metastasis after
treatment with EBRT. The influential study by Brierley
et al10 demonstrated an improvement in locoregional con-
trol and statistically significant improvements in those
patients receiving EBRT for papillary carcinoma who were
over the age of 60, with microscopic residual disease, T4
disease, and no metastases (10-year locoregional relapse-
free rate 86.4% with EBRT vs 65.7% with no EBRT;
p5 .01). Other studies reiterated significantly improved
locoregional control in similar subgroups with advanced
local disease and/or postoperative residual disease,8,12,13,16
but 2 large retrospective reviews failed to show any differ-
ence overall in locoregional control in patients who had
received EBRT compared with those who had not.8,9
Survival
Survival outcomes were reported variably among the
studies and, in general, follow-up was not long enough to
demonstrate survival effects. Only 3 studies reported a
statistically significant improvement in survival in
patients treated with EBRT, and these were all found in
subgroup or multivariate analysis rather than the main
study population.8,10,16 Brierley et al10 reported a large
retrospective cohort study, which demonstrated improved
cause-specific survival (CSS) over a median follow-up of
11.3 years in patients> 60 years of age with microscopic
residual disease, no gross residual disease, and no metas-
tasis who received EBRT. They also showed improved
CSS in patients >60 years with T4 disease and no gross
FIGURE 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2009 flow diagram. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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residual disease after surgery who were treated with
EBRT. Tsang et al8 also reported an improved CSS in a
subgroup of patients with papillary carcinoma and postop-
erative microscopic residuum (100% 10-year CSS vs 95%
without EBRT; p5 .038). Chow et al16 demonstrated
improved 10-year CSS (from 49.7% to 74.1%; p5 .01) in
patients with gross locoregional residual disease from
their cohort study of 1297 patients. Although not statisti-
cally significant, Kwon et al19 reported a cohort of
patients who all received EBRT plus surgery for DTC of
varying stages. They showed an overall survival rate of
97% with a median follow-up duration of 73 months,
which compared favorably with previously reported
cohorts of patients not treated with EBRT, who were
likely to have less advanced DTC.
Adverse effects
There were 16 reports of grade 3 to 4 EBRT complica-
tions, which included 1 patient who required a tracheos-
tomy for chronic laryngeal edema,7 2 patients with severe
dysphagia,14,15 and 13 patients with acute tracheitis or
esophagitis requiring hospital admission.8 In addition,
Schwartz et al20 reported 10 patients who suffered
adverse effects after EBRT of a cohort of 131 patients,
but did not include the grade of complication. Eight of
these were related to esophageal stricture, and 2 were
related to laryngeal edema and subglottic stenosis. They
reported a significantly lower complication rate with
IMRT as opposed to standard EBRT (2% vs 12%).
Quality assessment
Both reviewers assessed each trial against 13 criteria,
including sample size, follow-up period, study design,
clarity of description of aims, recruitment, inclusion and
exclusion criteria, intervention, and outcomes. The aver-
age quality assessment score was 13 of 26 (range, 9–18).
This was felt to be acceptable, as the nature of most of
the studies precluded them from scoring for prospective
design, randomization, and blinding. All except 1 study
were single center, retrospective studies with potential for
significant bias. There was significant clinical and meth-
odological heterogeneity among the studies because of
varying inclusion criteria, interventions, and outcome
reporting.
Quantitative analysis
Eight studies were deemed suitable for quantitative
analysis because of their ability to fulfil the eligibility cri-
teria, inclusion and comparison of EBRT and non-EBRT
treatment cohorts, and comprehensive reporting of locore-
gional control outcomes.7,10–15,17,21 These comprised
2388 patients with a male to female ratio of 1:3.2 and an
average age of 47.3 years. The primary tumor was T1 or
T2 in 36.3% of patients and T3 or T4 in 67.7%, and there
was regional nodal involvement in 44.3%, and distant
metastasis in only 4.4%. Extracapsular extension of the
primary tumor was noted in 58.9% of cases across the 8
studies, regardless of the treatment prescribed.
There was significant variation in treatment approaches
between studies. The vast majority of patients underwent
complete or subtotal thyroidectomy with or without neck
dissection, followed by radioiodine therapy, EBRT, or
both. Overall, 645 patients received EBRT and 1743 did
not. Unfortunately, 2 studies did not report the number of
patients who received EBRT and radioiodine therapy in
combination.10,11 After excluding these studies, only
16.1% of the patients who received EBRT did not also
receive radioiodine therapy. It was not felt that these
patients should be excluded from this review, as the rea-
son for prescribing EBRT but not radioiodine therapy was
poor tumor uptake of iodine in all cases. It was assumed
that this was determined by postoperative radionuclide
studies, although this is only explicitly stated in 1 study.13
Radiation doses ranged from 45 to 70 Gray over variable
TABLE 2. Intervention treatment groups
Study Year
No. of
patients
Total no.
receiving EBRT
Treatment groups
Surgery1 EBRT Surgery1 EBRT1RAI Surgery1 RAI
Surgery
alone
EBRT
alone EBRT1RAI
Biermann et al7 2009 351 26 0 26 325 0 0 0
Tsang et al8 1996 382 185 51 123 92 97 6 0
Lin et al9 1997 699 72 72 * * * * *
Brierley et al10 2005 729 318 * * * * * *
Chow et al11 2002 842 105 * * * * * *
Keum et al12 2006 68 25 24 1 13 30 0 0
Kim et al13 2003 91 23 11 12 68 0 0 0
Kim et al14 2010 23 23 4 19 0 0 0 0
Philips et al15 1993 94 38 0 38 56 0 0 0
Chow et al16 2006 1297 192 28 163 817 289 0 0
Farahati et al17 1996 169 99 99 70 0 0 0
Kwon et al19 2013 39 39 36 3 * * * *
Schwartz et al20 2008 131 131 12 119 0 0 0 0
Chen et al21 2009 44 11 3 8 33 0 0 0
Meadows et al22 2006 42 42 22 14 0 0 5 1
O’Connell et al23 1994 113 113 56 74 0 0 0 0
Abbreviations: EBRT, external beam radiotherapy; RAI, radioactive iodine treatment.
* Data not available.
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periods of time, but radiation treatment was not described
in detail.
Where possible, data on the EBRT and no-EBRT
groups in each study were collected and locoregional con-
trol in the 2 groups was compared. There was no statisti-
cally significant difference in sex or nodal involvement
between the 2 groups. Unfortunately, the studies on the
whole did not report the T classification breakdown of
those who received EBRT and those who did not,
although one could reasonably assume that those who did
receive EBRT had mainly T3 and T4 disease. This is
likely to confound analysis of survival and recurrence in
the 2 groups. Nevertheless, the mean recurrence rate in
the pooled patients receiving EBRT regardless of stage or
residual disease status was 8%, and in those who did not
receive EBRT it was 25%, a statistically significant dif-
ference (p5 .0313).
DISCUSSION
This review highlights the lack of good evidence for
the use of EBRT in DTC. Furthermore, it is clear that
there is wide variation in how it is used around the world.
Although there is no consensus in the published literature
on the indications for EBRT in DTC, most available evi-
dence suggests improved locoregional control in certain
patients. This is supported by quantitative analysis of
reported overall locoregional control rates, which show a
large statistically significant difference in favor of those
who received EBRT.
Lack of statistically significant differences in survival
outcomes is not surprising, considering the relatively
small number of cases but also the indolent nature and
favorable prognosis of most DTC cases. A large retro-
spective analysis showed a 98.6% cancer-specific survival
rate among patients with DTC.24 Such a survival rate
requires very large numbers to show any statistically sig-
nificant improvement. With advances in modern imaging
technology, DTC is being diagnosed at an earlier stage,
and fewer patients are candidates for EBRT. This high-
lights the importance of conducting multicenter studies
with large numbers.
The reduced rate of locoregional recurrence in patients
who received EBRT, reported in most of the studies, is
particularly interesting given the poorer prognosis of
those for whom EBRT is generally prescribed. Some
studies report a statistically significant improvement in
locoregional control in the overall cohort of patients who
received EBRT as well as matched subgroups with simi-
lar risk factors, such as T4 disease and age.10,11
Importantly, the 2 studies that failed to show an
improvement in locoregional control with EBRT were
older studies.8,9 The improvement in modern radiotherapy
technology and techniques may account for the better out-
comes in more recent studies. It is only in the last 10 to
15 years that IMRT has become readily available, as it
relies upon precise 3D imaging technology and computer-
controlled IMRT beams during treatment.25,26 Now
widely used, this form of treatment delivers better spar-
ing, thus allowing refinement of clinical target volume.
Treatment regimes and the dose-response relationship in
IMRT are likely to improve treatment outcomes in the
future.
Radioiodine therapy is the first line adjuvant treatment
for DTC because of its high specificity for tumor tissue
and favorable side effect profile. However, a small pro-
portion of DTC is resistant or refractory to radioiodine
therapy.27 This group may benefit from EBRT. The
adverse effects of EBRT in the head and neck are well
documented and, although mostly mild, life-threatening
cases, such as spinal cord necrosis, have been reported in
patients with thyroid carcinoma.28 Possible long-term
effects, such as second primary malignancy, could not be
assessed because of insufficient follow-up. For these rea-
sons as well as the favorable prognosis of DTC in
younger patients,24 most authors only recommend EBRT
in patients with DTC older than 45 years.
CONCLUSION
Despite the heterogeneous populations, varied inclusion
criteria, and retrospective designs of the studies consid-
ered in this review, they do provide useful information to
the clinician treating DTC. There are large numbers of
patients from the pooled study cohorts and the evidence
from recent studies suggests an improvement in locore-
gional control when EBRT is used in patients at high risk
for locoregional recurrence and over the age of 45. Fur-
ther long-term multicenter prospective research is needed,
although the findings of this review suggest that EBRT is
an adjuvant treatment modality that should be considered
in such patients.
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